Role of Anti-angiogenesis in Ovarian Cancer Dr. Thomas Herzog

Role of the Anti-angiogenesis in Ovarian Cancer Dr. Thomas Herzog Day 1 2021Подробнее

Role of PARP Inhibitor in Ovarian Cancer Dr. Thomas HerzogПодробнее

Dr. Herzog on Novel Therapies in Ovarian CancerПодробнее

Thomas Herzog, MD: The Foundation for Women's CancerПодробнее

Dr. Herzog on the Use of HIPEC in Ovarian CancerПодробнее

Antiangiogenic Therapy in Ovarian Cancer ManagementПодробнее

Treatment of Recurrent Ovarian Cancer Dr. Thomas HerzogПодробнее

Updates on Frontline Treatment of Ovarian Cancer Dr. Thomas Herzog (Day1) 2021Подробнее

Front Line Treatment of Ovarian Cancer Dr. Thomas HerzogПодробнее

Novel Therapeutics - Ovarian Cancer Research Seminar SeriesПодробнее

Targeting VEGF in Advanced Ovarian CancerПодробнее

PARP Combination Therapies in Ovarian CancerПодробнее

Mechanisms of Anti-angiogenic Therapy in Lung CancerПодробнее

Immunotherapy in Gynecological Cancer Dr. Thomas HerzogПодробнее

Dr. Carol Aghajanian on the Angiogenesis Inhibitor Pazopanib in Ovarian CancerПодробнее

Antiangiogenic Agents in Ovarian CancerПодробнее

Dr. Herzog on the Optimal Use of Bevacizumab in Patients With Ovarian CancerПодробнее

ASCO 2015: A Focus on Gynecologic OncologyПодробнее

Professor Gordon Jayson: treating ovarian cancer with anti-angiogenic agentsПодробнее